Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.5, a high estimate of $22.00, and a low estimate of $18.00. This current average has increased by 4.45% from the previous average price target of $18.67.

Analyzing Analyst Ratings: A Detailed Breakdown

The perception of NeoGenomics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of NeoGenomics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on NeoGenomics analyst ratings.

Get to Know NeoGenomics Better

Financial Insights: NeoGenomics

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: NeoGenomics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.44%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: NeoGenomics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.55%, the company may face hurdles in effective cost management.

Return on Equity (ROE): NeoGenomics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.94%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): NeoGenomics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.08%, the company may face hurdles in achieving optimal financial performance.

Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.